{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T10:31:04Z","timestamp":1793442664395,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jconrel.2026.115408","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:56:14Z","timestamp":1790175374000},"page":"115408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PB","title":["Targeted dual degradation of GPC-3 and VEGFR with multivalent DNA nanoflower-based LYTACs for hepatocellular carcinoma therapy"],"prefix":"10.1016","volume":"399","author":[{"given":"Ping","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhi","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghao","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songbo","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115408_bb0005","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1136\/gutjnl-2024-332920","article-title":"Is mailed outreach and patient navigation a perfect solution to improve HCC screening?","volume":"73","author":"Radu","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2026.115408_bb0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.canlet.2019.12.029","article-title":"Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches","volume":"473","author":"Tagliamonte","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2026.115408_bb0015","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.jhep.2023.05.005","article-title":"Statistical perspectives on using hepatocellular carcinoma risk models to inform surveillance decisions","volume":"79","author":"Innes","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2026.115408_bb0020","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.115408_bb0025","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115408_bb0030","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2026.115408_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104069","article-title":"New insights into the mechanism of resistance to lenvatinib and strategies for lenvatinib sensitization in hepatocellular carcinoma","volume":"29","author":"Fan","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2026.115408_bb0040","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13046-025-03386-8","article-title":"Targeted inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: clinical implications","volume":"44","author":"Zhao","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115408_bb0045","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1756-9966-29-48","article-title":"Generation of functional CD8+ T cells by human dendritic cells expressing glypican-3 epitopes","volume":"29","author":"O\u2019Beirne","year":"2010","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115408_bb0050","article-title":"119 ADI-002: an IL-15 armored allogeneic \u2018off-the-shelf\u2019 V\u03b41 gamma delta CAR T cell therapy for solid tumors targeting glypican-3 (GPC3)","volume":"9","author":"Makkouk","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2026.115408_bb0055","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1002\/hep.30949","article-title":"Engineered anti-GPC3 immunotoxin, HN3-ABD-T20, produces regression in mouse liver cancer xenografts through prolonged serum retention","volume":"71","author":"Fleming","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2026.115408_bb0060","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/hep.23848","article-title":"The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation","volume":"52","author":"Lai","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2026.115408_bb0065","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/hep.23794","article-title":"Suppression of liver regeneration and hepatocyte proliferation in hepatocyte-targeted glypican 3 transgenic mice","volume":"52","author":"Liu","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2026.115408_bb0070","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2217\/imt-2020-0278","article-title":"Phase I studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma","volume":"13","author":"Ikeda","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jconrel.2026.115408_bb0075","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.ymthe.2021.01.006","article-title":"A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC","volume":"29","author":"Du","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115408_bb0080","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jhep.2016.04.015","article-title":"Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma","volume":"65","author":"Zhu","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2026.115408_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2023.111007","article-title":"The role and mechanism of HIF-1\u03b1-mediated glypican-3 secretion in hypoxia-induced tumor progression in hepatocellular carcinoma","volume":"114","author":"Wang","year":"2024","journal-title":"Cell. Signal."},{"key":"10.1016\/j.jconrel.2026.115408_bb0090","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1039\/D2CS00220E","article-title":"Chemistries of bifunctional PROTAC degraders","volume":"51","author":"Cao","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2026.115408_bb0095","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.tips.2023.05.008","article-title":"Leveraging aptamers for targeted protein degradation","volume":"44","author":"Yang","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2026.115408_bb0100","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-targeting chimaeras for degradation of extracellular proteins","volume":"584","author":"Banik","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115408_bb0105","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","article-title":"LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation","volume":"17","author":"Ahn","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.jconrel.2026.115408_bb0110","doi-asserted-by":"crossref","first-page":"44162","DOI":"10.1021\/jacs.5c13607","article-title":"Bifunctional LYTAC mediates hepatocytes-hepatic stellate cells crosstalk by regulating 5-HT2A receptor degradation and antagonism to synergistically ameliorate hepatic fibrosis","volume":"147","author":"Zhou","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2026.115408_bb0115","doi-asserted-by":"crossref","first-page":"8832","DOI":"10.1039\/D2CS00624C","article-title":"Emerging degrader technologies engaging lysosomal pathways","volume":"51","author":"Ding","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2026.115408_bb0120","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jconrel.2023.01.022","article-title":"\u201cHook&Loop\u201d multivalent interactions based on disk-shaped nanoparticles strengthen active targeting","volume":"354","author":"Dong","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115408_bb0125","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1021\/acs.biochem.8b00150","article-title":"Quantitative characterization of bivalent probes for a dual bromodomain protein, transcription initiation factor TFIID subunit 1","volume":"57","author":"Suh","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2026.115408_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.138609","article-title":"Rational design of N-glycosyltransferases from Aggregatibacter aphrophilus to synthesize gal-modified glycoconjugates targeting hepatocellular carcinoma cells","volume":"289","author":"Yu","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2026.115408_bb0135","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1038\/s41467-025-60039-2","article-title":"DNA nanoflower Oligo-PROTAC for targeted degradation of FUS to treat neurodegenerative diseases","volume":"16","author":"Ge","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115408_bb0140","article-title":"MG132 attenuates the replication of classical swine fever virus in vitro","volume":"11","author":"Chen","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.jconrel.2026.115408_bb0145","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/s41467-021-22111-5","article-title":"Molecular basis of V-ATPase inhibition by bafilomycin A1","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115408_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121967","article-title":"Effect of hydrophile-lipophile balance of the linker in Gal\/GalNAc ligands on high-affinity binding of galactosylated liposomes by the asialoglycoprotein receptor","volume":"624","author":"Nie","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115408_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116183","article-title":"Carrier-free self-assembled nanomedicine based on celastrol and galactose for targeting therapy of hepatocellular carcinoma via inducing ferroptosis","volume":"267","author":"Zhang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115408_bb0160","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s40001-024-02073-2","article-title":"The role of glypican-3 in hepatocellular carcinoma: insights into diagnosis and therapeutic potential","volume":"29","author":"Devan","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.jconrel.2026.115408_bb0165","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41420-022-01198-9","article-title":"A VEGFR targeting peptide-drug conjugate (PDC) suppresses tumor angiogenesis in a TACE model for hepatocellular carcinoma therapy","volume":"8","author":"Wang","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2026.115408_bb0170","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202504220","article-title":"Autophagy-mediated suppression of tumor growth by food-grade lipid nanoparticles in mice","volume":"12","author":"Peng","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2026.115408_bb0175","doi-asserted-by":"crossref","first-page":"7043","DOI":"10.7150\/ijbs.119176","article-title":"Synergistic anti-tumor effects of Sulfatinib and Kaempferol on pancreatic neuroendocrine tumors via CALCA-mediated PI3K\/AKT\/mTOR pathway","volume":"21","author":"Chen","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.jconrel.2026.115408_bb0180","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jconrel.2020.11.020","article-title":"Targeted delivery of siRNAs against hepatocellular carcinoma-related genes by a galactosylated polyaspartamide copolymer","volume":"330","author":"Perrone","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115408_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2017.07.030","article-title":"Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex","volume":"143","author":"Zhao","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2026.115408_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100647","article-title":"Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs","volume":"296","author":"Alabi","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2026.115408_bb0195","article-title":"DNA nanoflower LYTACs enable efficient VEGF degradation and verteporfin loading for combined therapy of wet age-related macular degeneration","volume":"13","author":"Li","year":"2026","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2026.115408_bb0200","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41392-026-02761-x","article-title":"Tetrahedral DNA nano-PROTACs enable enhanced ocular penetration and efficient nucleolin degradation for choroidal neovascularization therapy","volume":"11","author":"Song","year":"2026","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926008126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926008126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T09:41:57Z","timestamp":1793439717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926008126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":40,"alternative-id":["S0168365926008126"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115408","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted dual degradation of GPC-3 and VEGFR with multivalent DNA nanoflower-based LYTACs for hepatocellular carcinoma therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115408","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115408"}}